Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

NCRI 2019 | Interventional pharmoeconomics to reduce the cost of therapy

Mark Ratain • 4 Nov 2019
NCRI 2019
General Antibodies Atezolizumab

Mark Ratain, MD, University of Chicago, Chicago, IL, talks about how interventional pharmoeconomics can bring about the reduction in the cost of cancer therapies. Recorded at the 2019 National Cancer Research Institute (NCRI) Annual Cancer Conference, in Glasgow, UK.
For more information about the NCRI Cancer Conference, visit https://conference.ncri.org.uk.

More from Mark Ratain

4:06
Strategies to reduce drug costs
Mark Ratain • 4 Nov 2019

Related Videos

1:56
Phase I trial of trastuzumab deruxtecan and neratinib in HER2-altered tumors
Haeseong Park • 8 Apr 2024
2:45
Remaining challenges in treating solid tumors with CAR-Treg therapy
Leonardo Ferreira • 8 Apr 2024
2:01
Engineering chimeric antigen receptor regulatory T cells for treating cancer
Leonardo Ferreira • 8 Apr 2024
0:59
What challenges are there in using CAR-T cells for solid tumors?
Leonardo Ferreira • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals